Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience

Selvaggi, Luigi; Loizzi, Vera; Gilio, A. R. Di; Nardelli, Claudia; Cantatore, Clementina; Cormio, Gennaro

doi:10.1111/j.1525-1438.2006.00396.x

Cited by 25 publications

(19 citation statements)

References 18 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, no clinical trial has compared chemoradiation followed by surgery versus chemoradiation, even if the European Organization for Research and Treatment of Cancer (EORTC) has an ongoing randomized trial (EORTC 55994) which is investigating this issue. Until now, in many centers the alternative therapy to chemoradiation for locally advanced cervical cancer is neoadjuvant chemotherapy followed by radical surgery [25,26]. …”

Section: Discussionmentioning

confidence: 99%

Bowel Dysfunction following Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Prospective Study

et al. 2014

Self Cite

View full text Add to dashboard Cite

Objective: To objectively assess anorectal dysfunction following nerve-sparing radical hysterectomy in stage I-II cervical carcinoma patients. Material and Methods: Between 2008 and 2012, 21 patients with primary cervical cancer stage FIGO I-II were enrolled in this prospective study. All women underwent nerve-sparing radical hysterectomy. Anorectal manometry was performed preoperatively and 6 months after surgery. A paired Student t test was used to assess the statistical difference between the manometric evaluations. A p value <0.05 was considered statistically significant. Results: Twenty-one patients were available for follow-up. Maximal and mean anal resting and squeezing pressures were unaffected by the surgical procedure, rectoanal inhibitory reflex and length of the high anal pressure zone did not change after the operation. The minimal volume to elicit rectal sensation, urge to defecate and maximal tolerable volume did not change significantly in the postoperative period, although they decreased in 2 and increased in 3 patients. In addition, rectal compliance did not change after surgery. Furthermore, no significant differences were found between patients who were or were not treated with adjuvant radiotherapy. Conclusions: Our findings suggest that nerve-sparing radical hysterectomy for cervical cancer does not seem to be associated with long-term anorectal dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Bowel Dysfunction following Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Prospective Study

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ability of NACT to reduce tumour volume and virtually sterilize micrometastases may be due to an uncompromised tumour blood supply and a population of chemosensitive tumour cells. Thus, NACT allows for a less-extensive dissection of the cervix instead of radical hysterectomy while preserving the effectiveness of the treatment (Hwang et al, 2001;Selvaggi et al, 2006).…”

Section: Effect Of Laparoscopicmentioning

confidence: 99%

Effect of Laparoscopic Nerve-sparing Radical Hysterectomy on Bladder Function, Intestinal Function Recovery and Quality of Sexual Life in Patients with Cervical Carcinoma

Chen

Zhang²,

Zhang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To investigate bladder and intestinal function recovery and quality of sexual life after laparoscopic nerve-sparing radical hysterectomy (LNRH) for treatment of early invasive cervical carcinoma. Methods: Subjects included patients who underwent radical hysterectomy by laparotomy who were randomly assigned to 2 groups: 30 patients who underwent LNRH and 35 classical laparoscopic radical hysterectomy (LRH). We assessed the patients general clinical information, surgical characteristics, pathological findings, and adjuvant therapies. A urodynamic study was used to assess bladder function. Intestinal function recovery and quality of sexual life were evaluated by questionnaire. Results: No significant differences were found in age, surgery characteristics, pathological findings, adjuvant therapies, and main adverse effects between the 2 groups. The mean duration of the postoperative catheterization (DPC) in group LNRH was shorter than that in group LRH (P < 0.001). The maximum flow rate, maximum cystometric capacity , maximum detrusor pressure and urinary complications in group LNRH were better than those in group LRH. The quality of sexual life evaluated according to the female sexual function index (FSFI) was better in group LNRH than in those who underwent LRH. The intestinal function of patients in group LNRH also recovered better compared with patients in group LRH.

show abstract

“…In addition, CPT-11 has been prescribed for the treatment of small cell lung (3), breast (4), central nervous system (5), cervical (6), esophageal (7), gastric (8), and pancreatic (9) cancers as well as non -Hodgkin's lymphoma (10). The parent compound, camptothecin, is derived from the bark of the Chinese tree Camptotheca acuminata.…”

mentioning

confidence: 99%

Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model

Sapra

Zhao

Mehlig

et al. 2008

Clinical Cancer Research

162

148

View full text Add to dashboard Cite

Purpose: Clinical development of SN38, the active metabolite of camptothecin-11 (CPT-11), has been hampered due to its poor solubility. We have developed a novel polymer-drug conjugate, EZN-2208, made by linking SN38 with a multiarm polyethylene glycol via a glycine linker. Experimental Design: The in vitro cytotoxicity of EZN-2208 was tested using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. The therapeutic efficacy of EZN-2208 was evaluated in various xenografts, including an in vivoŝ elected CPT-11^refractory model. Tumor and blood concentration of EZN-2208, CPT-11, and SN38 was determined by high-performance liquid chromatography.Results: In vitro, EZN-2208 was 10-to 245-fold more potent than CPT-11in a panel of human tumor cell lines. In xenograft models of MX-1 breast, MiaPaCa-2 pancreatic, or HT-29 colon carcinoma, treatment with either a single dose or multiple injections of EZN-2208 was more efficacious (and in some cases produced tumor eradication for >16 weeks) compared with CPT-11 at their respective maximum tolerated doses or corresponding dose levels (P < 0.01).Most interestingly, EZN-2208 showed marked antitumor activity in animals that developed resistance to an 8-day course of CPT-11 treatment, as well as outperformed CPT-11 as secondround therapy in mice initially sensitive to CPT-11. EZN-2208 had prolonged circulation in the blood compared with CPT-11, resulting in high tumor exposure. This resulted in higher and longer-lasting tumor exposure of free SN38 in mice given EZN-2208 compared with those given CPT-11. Conclusions: Preclinical data suggest that EZN-2208 may be a promising anticancer agent in a wide variety of clinical settings, including tumors refractory to CPT-11treatment.

show abstract

Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience

Cited by 25 publications

References 18 publications

Bowel Dysfunction following Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Prospective Study

Bowel Dysfunction following Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Prospective Study

Effect of Laparoscopic Nerve-sparing Radical Hysterectomy on Bladder Function, Intestinal Function Recovery and Quality of Sexual Life in Patients with Cervical Carcinoma

Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model

Contact Info

Product

Resources

About